Table 2.
Change from baseline in the St George’s Respiratory Questionnaire−COPD score to week 56 (per-protocol population)*,†
| Overall | <200 cells per µL | ≥200 cells per µL | <300 cells per µL | ≥300 cells per µL | |
|---|---|---|---|---|---|
| Total | |||||
| Placebo | −4·43 (11·71; n=42) | −4·26 (10·17; n=21) | −4·79 (13·64; n=20) | −4·40 (11·04; n=34) | −5·11 (16·24; n=7) |
| Benralizumab | −5·51 (16·64; n=37) | −2·10 (16·47; n=20) | −9·52 (16·42; n=17) | −1·90 (14·97; n=25) | −13·03 (18·08; n=12) |
| p value | 0·739 | 0·614 | 0·345 | 0·463 | 0·354 |
| Symptom | |||||
| Placebo | −3·19 (17·44; n=42) | −5·56 (18·34; n=21) | −1·40 (16·79; n=20) | −3·88 (17·40; n=34) | −1·87 (19·35; n=7) |
| Benralizumab | −9·02 (21·27; n=37) | −3·22 (14·16; n=20) | −15·84 (26·24; n=17) | −3·40 (12·84; n=25) | −20·72 (30·00; n=12) |
| p value | 0·185 | 0·651 | 0·051 | 0·909 | 0·156 |
| Activity | |||||
| Placebo | −5·65 (14·85; n=42) | −5·09 (12·66; n=21) | −6·51 (17·44; n=20) | −6·06 (13·65; n=34) | −4·47 (21·78; n=7) |
| Benralizumab | −4·37 (24·89; n=37) | −3·96 (28·35; n=20) | −4·86 (20·94; n=17) | −1·91 (26·03; n=25) | −9·49 (22·52; n=12) |
| p value | 0·780 | 0·868 | 0·795 | 0·431 | 0·641 |
| Impacts | |||||
| Placebo | −4·16 (14·62; n=42) | −3·33 (14·95; n=21) | −4·99 (14·98; n=20) | −3·63 (14·77; n=34) | −6·61 (15·87; n=7) |
| Benralizumab | −4·95 (16·97; n=37) | −0·61 (17·04; n=20) | −10·06 (15·88; n=17) | −1·38 (16·57; n=25) | −12·40 (15·94; n=12) |
| p value | 0·826 | 0·589 | 0·324 | 0·585 | 0·455 |
*
Data are expressed as mean (SD; n). p values were calculated by ANCOVA. One patient in the placebo group did not have baseline blood eosinophil count, resulting in one patient less for subgroup analyses in this group. Not all patients in the per-protocol population had a change from baseline in St George’s Respiratory Questionnaire score across different timepoints.